No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CGEN Compugen
- 1.7353
- -0.0847-4.65%
Trading Jul 22 11:39 ET
155.36MMarket Cap-9640P/E (TTM)
1.8300High1.7300Low148.02KVolume1.8300Open1.8200Pre Close262.50KTurnover0.18%Turnover RatioLossP/E (Static)89.53MShares3.030152wk High2.60P/B146.97MFloat Cap0.530052wk Low--Dividend TTM84.70MShs Float19.9000Historical High--Div YieldTTM5.50%Amplitude0.3400Historical Low1.7730Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Shares of Compugen Down 3%, Iteos Therapeutics Down 6.1%, and Arcus Biosciences Down 3.8%
Roche's TIGIT therapy failed to achieve its main goal. Biotechnology stocks like Compugen (CGEN.US) suffered heavy losses before the market opened.
On Friday, following the failure of a similar drug being developed by Swiss pharmaceutical giant Roche in phase 2/3 clinical trials, the stock prices of some biotech companies developing a new type of anti-cancer drug (known as a new "anti-TIGIT therapy") have fallen significantly in pre-market trading. Roche's stock price also fell in the European stock market on Thursday. Earlier, the company stated that tiragolumab, its anti-TIGIT treatment drug as part of a frontline drug combination, was used in the SKYSCRAPER study for non-squamous non-small-cell lung cancer.
Roche's Setback in Lung Cancer Trial Sends Anti-TIGIT Developers Lower
Bridging Gaps + Building Futures: Compugen Partners With Sun Youth for Inclusive Education
Compugen Inc., the nation's largest privately-owned and operated Technology Ally, is proud to announce a philanthropic contribution to Sun Youth, a...
Compugen to Present at Upcoming Antibody Industrial Symposium
HOLON, Israel, June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced
Compugen (CGEN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Comments
$Compugen(CGEN.US$ 🤩
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
The market anticipates a decline in future revenue, possibly explaining the suppressed P/S. This weak revenue outlook could continue to pressure shares, making it hard to maintain current prices. Shareholders accept the low P/S, expecting future revenue may not bring pleasant surprises.
$Compugen(CGEN.US$ fk entered very early! now no option to hold at lesast 2 week or more !
$Compugen(CGEN.US$ 👀looks good i n game 🎲
Michelle Mahler's appointment as Chief Medical Officer is a positive step for Compugen, thanks to her vast clinical development experience. Her leadership in the COM503 Phase 1 study and future role in advancing COM701, COM902, and COM503 are anticipated to significantly boost the company's clinical development strategy.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg